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the treatment of painful recurrent soft plate
carcinoma by high-dose-rate mold brachytherapy:
A case reportMasayuki Matsuo a,*, Shinya Hayashi b, Sunaho Maeda b, Osamu Tanaka b,
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d Department of Oral Surgery, Gifu University, School of Medicine, 1-1 Yanaido, Gifu 501-1194, JapanReceived 2 May 2006; received in revised form 23 August 2006; accepted 22 September 2006Summary We herein report a case of the effectiveness of 4 Gy single fraction high-dose-
rate mold brachytherapy in the palliative treatment of a painful recurrent soft palate car-
cinoma in a previously irradiated field. A 73-year-old man with a painful recurrent squamous
cell carcinoma in the right soft palate in a previously irradiated field was treated with high-
dose-rate mold brachytherapy. Although only 4 Gy could be delivered, the patient showed a
reduction in the degree of pain in the right soft palate after the treatment. Unfortunately,
the patient died of interrecurrent disease with pleural metastases five months after the
brachytherapy.c 2006 Elsevier Ltd. All rights reserved.
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2The occurrence of a second head and neck cancer is esti-
mated to be approximately 20–40%.1,2 During the follow-up
of patients, who have undergone treatment for head and
neck cancer, the early diagnosis of a recurrent tumor is rel-
atively easy, but the choices of treatment for such patients741-9409/$ - see front matter c 2006 Elsevier Ltd. All rights reserved
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E-mail address: matsuo@kizawa.or.jp (M. Matsuo).tend to be limited. Curative surgery is often not possible
due to the extent of tumor spread and the patient’s overall
condition. A radical course of external beam radiotherapy in
a previously irradiated area is not possible without causing
excessive morbidity. The available techniques for re-irradi-
ation with high dose include afterloading iridium 192 im-
plants, which is a limited treatment with minimal
radiation to the surrounding normal tissue. Peiffert et al.3.
306 M. Matsuo et al.reported 73 patients with recurrent velotonsillar carcino-
mas treated using this approach. Recently, a less invasive
technique combining a mold and a remote afterloading unit
with an iridium 192 microsource has been used for the treat-
ment of superficial oral carcinoma.4–7 However as far as
could be ascertained, there have been few reports about
the use of mold techniques for the palliative salvage irradi-
ation of recurrent oropharyngeal cancer.
The purpose of this clinical report is to present the use of
4 Gy single fraction high-dose-rate mold brachytherapy in
the palliative management of painful recurrent soft palate
carcinoma in a previously irradiated field.
Case report
In April 2000, a 73-year-old man, who had a complained of
pain in his right soft palate demonstrated a tumoral lesion
that measured 25 · 20 mm. The findings of a histopatho-
logic examination of the specimen were consistent with
well-differentiated squamous cell carcinoma. The patients
was staged as T2N0M0 (UICC-TNM, 1997) cancer of the
right soft palate and was referred to our department in or-
der to undergo primary radiation therapy. External beam
irradiation (60 Gy/30 fractions/45 days) was performed
with a 4 MV beam by opposed lateral portals. The tumor
disappeared macroscopically after the treatment. In Au-
gust 2000, he presented with a recurrent carcinoma in
the right soft palate in a previously irradiated field, he
was retreated with external beam irradiation (30 Gy/15
fractions/23 days) with a 4 MV beam by opposed lateral
portals. After treatment, no change in tumor size was ob-
served afterwards. In March 2001, the patient was referred
to our department for a work up because of soft palate
pain. He presented with tumor regrowth in the right soft
palate in a previously irradiated field, and the computed
tomography (CT) showed painless multiple bone metasta-
ses. It was decided by the medical team that chemother-
apy was contraindicated because of renal failure and heFigure 1 Four mold catheters are embedded in parallel
approximately 10 mm apart (black arrow) and at a distance of
5 mm from the mold surface they were laid in parallel to cover
the tumor area (white arrow).also rejected morphine pharmaceutical use because of se-
vere vomiting. As a result, high-dose-rate mold radiother-
apy with Microselectron-HDR (Nucletron, Veenendaal, The
Netherlands) was employed in order to administer pallia-
tive radiotherapy at a site of recurrent right soft palate
carcinoma in a previously irradiated field. A dental mold
was made of resin to fit the jaw, and then four flexible
afterloading tubes, which were approximately 10 mm apart
from one another, which were located about 5 mm away
from the mold surface, were laid parallel to cover the tu-
mor area (Fig. 1). Next, the mold was thickened to mini-
mize radiation to the tongue and the mandible. The dose
distribution was calculated to obtain a reference dose of
4 Gy at the mold surface, which was then attached to
the tumor. Although a total dose of 12 Gy was intended
to be delivered by high-dose-rate mold radiotherapy three
times in just one week, only 4 Gy could be delivered just
one time because of the patients condition. Thereafter the
tumor did not increased in size and the patient showed a
reduction of the pain in the right soft palate region and
demonstrated an improved eating ability after the treat-
ment. No medication was prescribed for pain during and
following treatment. However, the patient later experi-
enced dyspnea due to pleural effusion in the fourth month
of follow-up. Thereafter his condition gradually deterio-
rated and he eventually died of interrecurrent disease with
pleural metastases five months after undergoing the
brachytherapy.Discussion
First primary head and neck tumors are generally treated by
radiotherapy or surgery. When patients are treated with
external beam irradiation for a cancer of the upper aerodi-
gestive tract, because of its fairly central location, the oro-
pharynx is almost always included in the treatment volume
for the oral cavity, pharynx, and larynx carcinomas. In addi-
tion, the minimum dose delivered to this volume tend to
usually be over 50 Gy. The re-irradiation of an infield second
primary tumor or recurrent tumor with optimum dose exter-
nal beam irradiation with a curative intent is not possible
without causing excessive morbidity.2 In contrast, brachy-
therapy tends to be well tolerated. This can be explained
by the small target volume and the modalities of treatment,
and the systematical use of mandibular lead shielding to
avoid osteoradionecrosis. Some investigators recommended
brachytherapy for treatment of early second primary tu-
mors of the velotonsillar area, which develop in a previously
radiated area. Recently, a less invasive technique combin-
ing a mold and a remote afterloading unit with a iridium
192 microsource has been used in a superficial oral carci-
noma.3–7 There have been some reports in the literature
on the use of high-dose-rate mold brachytherapy combined
with or without external beam therapy.4,7 These reports
seemed to indicate that high-dose-rate mold brachytherapy
alone may be useful for the management of early stage can-
cers with a satisfactory control.
In this case, although the recurrence locus was not a
superficial oral carcinoma, we presumed that less invasive
high-dose-rate mold brachytherapy may nevertheless be
effective in not only the early stage of oropharyngeal can-
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cancer in a previously irradiated field. Peiffert et al.3 re-
ported that 60 Gy by brachytherapy alone is the optimal
treatment for patients presenting with velotonsillar carci-
noma in a previously irradiated field. We therefore planned
a dose of mold therapy, which was regarded to be similar to
brachytherapy, however, the patient was irradiated with 60
Gy in the first treatment time and with 30 Gy at the first
time of recurrence point, therefore a total dose of 12 Gy
was intended to be delivered by high-dose-rate mold brach-
ytherapy three times for just one week. However, because
of the patient’s condition, only 4 Gy could be delivered at
one time. In the fifth month of the follow-up after mold
therapy, even though the tumor had not decreased in size,
the patient demonstrated a decrease of the pain in the right
soft palate after the treatment and the patient’s quality of
life was thus considered to have improved.
For the palliation of metastatic bone pain for at least 12
months, a single fraction of 8 Gy is reported to be a safe and
effective multifraction regimen.8 In this case, a 4 Gy single
fraction high-dose-rate mold brachytherapy may be effec-
tive for a painful recurrent soft palate tumor in a previously
irradiated area.
Based on the above findings, the use of mold therapy was
thus considered to be appropriate for the palliation of pain-
ful recurrent cancer because it is noninvasive and the ther-
apy had short duration. There are still too few cases that
have been treated by this therapy for the management of
a painful recurrent cancer in a previously irradiated field
by a 4 Gy single fraction high-dose-rate mold brachytherapy
for any definitive conclusion to be made. Therefore more
patients should be treated to determine the safety, effec-
tiveness, the optimal dose and fractionation of this therapy.Conflict of interest
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